At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Carboplatin +1 moredrug
Likely dose
Abraxane 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LCI-LUN-ABR-001: A Pilot Study of Carboplatin With Nab-Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer of Squamous Histology
In Brief
A Phase 2 clinical trial evaluating Carboplatin and Abraxane for Lung Cancer. Completed, enrolled 11 participants across 1 site.
Detailed Summary
ABRAXANE, based on results from prior studies, is a promising drug in squamous cell carcinoma of the lung. This study will help to explore the combination of ABRAXANE and carboplatin more thoroughly in the subgroup of patients who had the best response in prior studies as well as determine whether there are any biomarkers which can predict for response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedDec 2014
Primary CompletionJun 2017
Study CompletionDec 2019
TodayJul 2026
First PostedDec 31, 2014
Enrollment StartDec 1, 2014
Primary CompletionJun 15, 2017
Study CompletionDec 6, 2019
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.5 years ago
Interventions
Carboplatindrug
Dosing: AUC = 6; on Day 1
Abraxanedrug
100 mg/m\^2; Days 1, 8, 15